ApoE genotype accounts for the vast majority of AD risk and AD pathology
- Author
- RABER, Jacob1 ; HUANG, Yadong2 ; ASHFORD, J. Wesson3
[1] Departments of Behavioral Neuroscience and Neurology, L470, Division of Neuroscience, ONPRC, Oregon Health and Science University, 3181 S. W Sam Jackson Park Road, Portland, OR 97201, United States
[2] Gladstone Institute of Neurological Disease, Department of Pathology, University of California, San Francisico, CA, United States
[3] Stanford/VA Alzheimer's Center VA Medical Center, Palo Alto, CA, United States - Conference title
- Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003
- Conference name
- Challenging Views of Alzheimer's Disease. Conference (2 ; Cincinnati, Ohio 2003-07-24)
- Author (monograph)
- ROBINSON, Stephen R (Editor)2 ; CRUTCHER, Keith A (Editor)1
[1] Department of Neurosurgery, University of Cincinnati, College of Medicine, 231 Albert Sabin Way, Cincinnati, OH 45267-0515, United States
[2] School of Psychology, Psychiatry and Psychological Medicine, Monash University, Clayton, Vic., Australia - Source
Neurobiology of aging. 2004, Vol 25, Num 5, pp 641-650, 10 p ; ref : 64 ref
- CODEN
- NEAGDO
- ISSN
- 0197-4580
- Scientific domain
- Gerontology geriatrics; Neurology; Physiology, morphology
- Publisher
- Elsevier Science, London
- Publication country
- United Kingdom
- Document type
- Conference Paper
- Language
- English
- Author keyword
- AD pathology AD risk ApoE genotype
- Keyword (fr)
- Apolipoprotéine E Démence Alzheimer Facteur risque Génotype Sénescence Encéphale pathologie Maladie dégénérative Système nerveux central pathologie Système nerveux pathologie
- Keyword (en)
- Apolipoprotein E Alzheimer disease Risk factor Genotype Senescence Cerebral disorder Degenerative disease Central nervous system disease Nervous system diseases
- Keyword (es)
- Apolipoproteína E Demencia Alzheimer Factor riesgo Genotipo Senescencia Encéfalo patología Enfermedad degenerativa Sistema nervosio central patología Sistema nervioso patología
- Classification
- Pascal
- 002 Biological and medical sciences / 002B Medical sciences / 002B17 Neurology / 002B17G Degenerative and inherited degenerative diseases of the nervous system. Leukodystrophies. Prion diseases
- Discipline
- Neurology
- Origin
- Inist-CNRS
- Database
- PASCAL
- INIST identifier
- 15895940
Sauf mention contraire ci-dessus, le contenu de cette notice bibliographique peut être utilisé dans le cadre d’une licence CC BY 4.0 Inist-CNRS / Unless otherwise stated above, the content of this bibliographic record may be used under a CC BY 4.0 licence by Inist-CNRS / A menos que se haya señalado antes, el contenido de este registro bibliográfico puede ser utilizado al amparo de una licencia CC BY 4.0 Inist-CNRS
Access to the document
Install on your browser
DOI
10.1016/j.neurobiolaging.2003.12.023 
https://dx.doi.org/10.1016/j.neurobiolaging.2003.12.023
"O:13:\"PanistOpenUrl\":36:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000idc\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Neurobiology of aging\";s:9:\"\u0000*\u0000stitle\";s:16:\"Neurobiol. aging\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"641\";s:8:\"\u0000*\u0000epage\";s:3:\"650\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0197-4580\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RABER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Jacob\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:13:\"HUANG, Yadong\";i:1;s:18:\"ASHFORD, J. Wesson\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEAGDO\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003\";s:8:\"\u0000*\u0000title\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Panist access
"O:12:\"IstexOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Neurobiology of aging\";s:9:\"\u0000*\u0000stitle\";s:16:\"Neurobiol. aging\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"641\";s:8:\"\u0000*\u0000epage\";s:3:\"650\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0197-4580\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RABER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Jacob\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:13:\"HUANG, Yadong\";i:1;s:18:\"ASHFORD, J. Wesson\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEAGDO\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003\";s:8:\"\u0000*\u0000title\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Istex access
"O:16:\"UnpaywallOpenUrl\":35:{s:8:\"\u0000*\u0000email\";s:27:\"assistance-portail@inist.fr\";s:6:\"\u0000*\u0000fmt\";N;s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";N;s:7:\"\u0000*\u0000pmid\";N;s:9:\"\u0000*\u0000atitle\";N;s:9:\"\u0000*\u0000jtitle\";N;s:9:\"\u0000*\u0000stitle\";N;s:7:\"\u0000*\u0000date\";N;s:9:\"\u0000*\u0000volume\";N;s:8:\"\u0000*\u0000issue\";N;s:8:\"\u0000*\u0000spage\";N;s:8:\"\u0000*\u0000epage\";N;s:8:\"\u0000*\u0000pages\";N;s:7:\"\u0000*\u0000issn\";N;s:8:\"\u0000*\u0000eissn\";N;s:9:\"\u0000*\u0000aulast\";N;s:10:\"\u0000*\u0000aufirst\";N;s:9:\"\u0000*\u0000auinit\";N;s:10:\"\u0000*\u0000auinitm\";N;s:5:\"\u0000*\u0000au\";N;s:9:\"\u0000*\u0000aucorp\";N;s:7:\"\u0000*\u0000isbn\";N;s:8:\"\u0000*\u0000coden\";N;s:8:\"\u0000*\u0000genre\";N;s:7:\"\u0000*\u0000part\";N;s:9:\"\u0000*\u0000btitle\";N;s:8:\"\u0000*\u0000title\";N;s:8:\"\u0000*\u0000place\";N;s:6:\"\u0000*\u0000pub\";N;s:10:\"\u0000*\u0000edition\";N;s:9:\"\u0000*\u0000tpages\";N;s:9:\"\u0000*\u0000series\";N;s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";N;}"
Unpaywall access
"O:16:\"EuropePMCOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Neurobiology of aging\";s:9:\"\u0000*\u0000stitle\";s:16:\"Neurobiol. aging\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"641\";s:8:\"\u0000*\u0000epage\";s:3:\"650\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0197-4580\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RABER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Jacob\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:13:\"HUANG, Yadong\";i:1;s:18:\"ASHFORD, J. Wesson\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEAGDO\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003\";s:8:\"\u0000*\u0000title\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Europe PubMed Central access
"O:11:\"BaseOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Neurobiology of aging\";s:9:\"\u0000*\u0000stitle\";s:16:\"Neurobiol. aging\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"641\";s:8:\"\u0000*\u0000epage\";s:3:\"650\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0197-4580\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RABER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Jacob\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:13:\"HUANG, Yadong\";i:1;s:18:\"ASHFORD, J. Wesson\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEAGDO\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003\";s:8:\"\u0000*\u0000title\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
Base Search access
"O:12:\"ArXivOpenUrl\":35:{s:10:\"\u0000*\u0000openUrl\";N;s:6:\"\u0000*\u0000fmt\";s:10:\"proceeding\";s:6:\"\u0000*\u0000doi\";s:36:\"10.1016\/j.neurobiolaging.2003.12.023\";s:6:\"\u0000*\u0000pii\";s:0:\"\";s:7:\"\u0000*\u0000pmid\";s:0:\"\";s:9:\"\u0000*\u0000atitle\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:9:\"\u0000*\u0000jtitle\";s:21:\"Neurobiology of aging\";s:9:\"\u0000*\u0000stitle\";s:16:\"Neurobiol. aging\";s:7:\"\u0000*\u0000date\";s:4:\"2004\";s:9:\"\u0000*\u0000volume\";s:2:\"25\";s:8:\"\u0000*\u0000issue\";s:1:\"5\";s:8:\"\u0000*\u0000spage\";s:3:\"641\";s:8:\"\u0000*\u0000epage\";s:3:\"650\";s:8:\"\u0000*\u0000pages\";s:0:\"\";s:7:\"\u0000*\u0000issn\";s:9:\"0197-4580\";s:8:\"\u0000*\u0000eissn\";s:0:\"\";s:9:\"\u0000*\u0000aulast\";s:5:\"RABER\";s:10:\"\u0000*\u0000aufirst\";s:5:\"Jacob\";s:9:\"\u0000*\u0000auinit\";s:0:\"\";s:10:\"\u0000*\u0000auinitm\";s:0:\"\";s:5:\"\u0000*\u0000au\";a:2:{i:0;s:13:\"HUANG, Yadong\";i:1;s:18:\"ASHFORD, J. Wesson\";}s:9:\"\u0000*\u0000aucorp\";s:0:\"\";s:7:\"\u0000*\u0000isbn\";s:0:\"\";s:8:\"\u0000*\u0000coden\";s:6:\"NEAGDO\";s:8:\"\u0000*\u0000genre\";s:10:\"proceeding\";s:7:\"\u0000*\u0000part\";s:0:\"\";s:9:\"\u0000*\u0000btitle\";s:90:\"Challenging Views of Alzheimer's Disease-Round II, Cincinnati, Ohio, USA, July 24-27, 2003\";s:8:\"\u0000*\u0000title\";s:72:\"ApoE genotype accounts for the vast majority of AD risk and AD pathology\";s:8:\"\u0000*\u0000place\";s:6:\"London\";s:6:\"\u0000*\u0000pub\";s:16:\"Elsevier Science\";s:10:\"\u0000*\u0000edition\";s:0:\"\";s:9:\"\u0000*\u0000tpages\";s:2:\"10\";s:9:\"\u0000*\u0000series\";s:0:\"\";s:8:\"\u0000*\u0000proxy\";s:30:\"http:\/\/proxyout.inist.fr:8080\/\";s:12:\"\u0000*\u0000integrite\";b:1;}"
arXiv access
